Trials / Terminated
TerminatedNCT04652258
Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy
A Phase II, Open Label, Single Arm, Single Center Study to Evaluate Pyrexia Management (with or Without Any Other Cytokine Release Symptoms) Using Tocilizumab, an Humanized Monoclonal Antibody Against the Interleukin - 6 Receptor in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- University of Zurich · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study examines the development of fever after administration of Actemra (tocilizumab) in patients who have fever and other cytokine release symptoms (headache, nausea, palpitations, low blood pressure) due to cancer therapy (Tafinlar (dabrafenib) / Mekinist (trametinib) +/- immunotherapy) . The goal of the study is to better understand the side effects and to find an effective therapy against them.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Actemra | Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min. |
Timeline
- Start date
- 2021-02-01
- Primary completion
- 2021-10-31
- Completion
- 2021-10-31
- First posted
- 2020-12-03
- Last updated
- 2024-11-01
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT04652258. Inclusion in this directory is not an endorsement.